From Earlier: Exelixis Announces Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients with Hepatocellular Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) yesterday reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.